Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

Completed

• Conditions: Glaucoma, Open-angle
• Interventions: Drug: Xalacom

• Registration Number: NCT00801437
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma

Detailed Description

according to physicians decision, patients who met inclusion and exclusion criteria and sign the ICD

Study Timeline

• Study Start: 2008-10
• Study First Submitted: 2008-11-19
• Study First Submitted QC: 2008-12-02
• Study First Posted: 2008-12-03
• Primary Completion: 2009-06
• Study Completion: 2009-06
• Status Verified: 2011-06
• Last Update Submitted: 2021-02-17
• Last Update Posted: 2021-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 457

Inclusion Criteria

• primary open angle glaucoma
• ocular hypertension
• age >18 years

Exclusion Criteria

• bradycardia
• obstructive pulmonary disease
• hypersensitivity to the drug

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Xalacom treatment	Xalacom	patients with primary glaucoma

Primary Outcome Measures

Name	Time	Method
Incidence of ocular hyperemia	12 months
safety of treatment	12 months

Secondary Outcome Measures

Name	Time	Method
effectiveness in IOP lowering	12 months

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇸🇰 Zvolen, Slovakia